

Jing Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2385636/publications.pdf>

Version: 2024-02-01

16
papers

176
citations

1163117

8
h-index

1125743

13
g-index

16
all docs

16
docs citations

16
times ranked

296
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary central nervous system lymphoma in the United States, 1975â€“2017. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072110661.	2.5	14
2	Chest CT Findings and Differential Diagnosis of <i>Mycoplasma pneumoniae</i> Pneumonia and <i>Mycoplasma pneumoniae</i> Combined with Streptococcal Pneumonia in Children. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.9	17
3	Nomogram for Predicting the Overall Survival of Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma: A SEER- Based Study. <i>Frontiers in Oncology</i> , 2020, 10, 1093.	2.8	9
4	A novel mutation in the JAK2 gene (R588S) in a Chinese patient with erythrocytosis. <i>Annals of Hematology</i> , 2020, 100, 2643-2645.	1.8	0
5	Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation. <i>JAMA Network Open</i> , 2020, 3, e2017652.	5.9	30
6	<p>Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5879-5885.	2.0	3
7	Clonal evolution in a chronic neutrophilic leukemia patient. <i>Hematology</i> , 2019, 24, 455-458.	1.5	3
8	Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients. <i>Oncotarget</i> , 2017, 8, 9708-9716.	1.8	9
9	Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP. <i>Medicine (United States)</i> , 2016, 95, e4893.	1.0	17
10	Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP. <i>Clinica Chimica Acta</i> , 2016, 459, 150-154.	1.1	18
11	MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Histology and Histopathology</i> , 2016, 31, 285-92.	0.7	7
12	Combination of Bcl-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma. <i>OncoTargets and Therapy</i> , 2015, 8, 2645.	2.0	10
13	MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. <i>Tumor Biology</i> , 2014, 35, 6757-6762.	1.8	19
14	Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of diffuse large B cell lymphoma: a meta-analysis. <i>Tumor Biology</i> , 2013, 34, 3587-3591.	1.8	3
15	Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis. <i>Tumor Biology</i> , 2013, 34, 1467-1471.	1.8	3
16	Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. <i>Medical Oncology</i> , 2010, 27, 1082-1088.	2.5	14